| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Alan D D'Andrea | |
| Toshiyasu Taniguchi | |||
| P2860 | cites work | Biallelic inactivation of BRCA2 in Fanconi anemia | Q29616130 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| Fanconi anemia | Q845779 | ||
| P304 | page(s) | 4223-4233 | |
| P577 | publication date | 2006-02-21 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Molecular pathogenesis of Fanconi anemia: recent progress | |
| P478 | volume | 107 |
| Q58544520 | A Case of Superficial Esophageal Cancer in a Fanconi Anemia Patient that was Treated Successfully by Endoscopic Submucosal Resection |
| Q38357627 | A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response |
| Q35483796 | A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency |
| Q36189726 | A case report of Fanconi anemia diagnosed by genetic testing followed by prenatal diagnosis |
| Q28118199 | A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay |
| Q37004779 | A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network |
| Q39107105 | A hidden role of the inactivated FANCD2: upregulating ΔNp63. |
| Q57943496 | A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia |
| Q36922848 | A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function |
| Q33528298 | A novel germline PALB2 deletion in Polish breast and ovarian cancer patients |
| Q39897904 | A role for monoubiquitinated FANCD2 at telomeres in ALT cells |
| Q30436823 | ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function |
| Q38660676 | Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer |
| Q36835902 | Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia |
| Q38136395 | Advances in the understanding of the Fanconi anemia tumor suppressor pathway |
| Q92154522 | Assembly of a G-Quadruplex Repair Complex by the FANCJ DNA Helicase and the REV1 Polymerase |
| Q43497475 | Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis |
| Q24621546 | Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks |
| Q37005060 | Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. |
| Q33531604 | BACH1/FANCJ acts with TopBP1 and participates early in DNA replication checkpoint control |
| Q39847864 | BLM promotes the activation of Fanconi Anemia signaling pathway |
| Q24632998 | BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair |
| Q36771826 | BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q28590758 | BRCA2 is required for neurogenesis and suppression of medulloblastoma |
| Q34597168 | Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer |
| Q38804207 | Biochemical and cell biological assays to identify and characterize DNA helicase inhibitors |
| Q37168650 | CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors |
| Q38822073 | CRISPR-Cas9 technology and its application in haematological disorders |
| Q43167418 | CXCR4 induction in hematopoietic progenitor cells from Fanca(-/-), -c(-/-), and -d2(-/-) mice. |
| Q33368870 | Cancer incidence in relatives of British Fanconi Anaemia patients |
| Q34432871 | Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas |
| Q59565062 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial |
| Q28252640 | Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights |
| Q45868501 | Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy |
| Q42873308 | Chromosomal Breakage Study in Children Suspected With Fanconi Anemia in the Indian Population |
| Q37004481 | Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. |
| Q33441764 | Common Variable Immunodeficiency Caused by FANC Mutations |
| Q36791430 | Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California |
| Q37033646 | Contributions of DNA interstrand cross-links to aging of cells and organisms |
| Q42417139 | Correction of Fanconi Anemia Group C Hematopoietic Stem Cells Following Intrafemoral Gene Transfer |
| Q33374981 | Current diagnosis of inherited bone marrow failure syndromes |
| Q36927047 | DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention |
| Q29615572 | DNA repair pathways as targets for cancer therapy |
| Q36483479 | DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair |
| Q38788563 | Dental Perspective of Rare Disease of Fanconi Anemia: Case Report with Review |
| Q37146035 | Diagnosis of Fanconi anemia in patients with bone marrow failure |
| Q34047496 | Differential behaviour of normal, transformed and Fanconi's anemia lymphoblastoid cells to modeled microgravity |
| Q41518046 | Discovering the hidden sub-network component in a ranked list of genes or proteins derived from genomic experiments |
| Q30489278 | Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. |
| Q36004703 | Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies |
| Q40052370 | Disruption of the FA/BRCA pathway in bladder cancer |
| Q34786598 | Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide |
| Q93204695 | Dysfunctional DNA repair pathway via defective FANCD2 gene engenders multifarious exomic and transcriptomic effects in Fanconi anemia |
| Q36437240 | Dysfunctional telomeres in primary cells from Fanconi anemia FANCD2 patients |
| Q41574502 | FANCD2 and DNA Damage. |
| Q24307531 | FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3 |
| Q24303906 | FANCI is a second monoubiquitinated member of the Fanconi anemia pathway |
| Q28250124 | FANCI protein binds to DNA and interacts with FANCD2 to recognize branched structures |
| Q37391123 | FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress |
| Q30863349 | FANCJ helicase uniquely senses oxidative base damage in either strand of duplex DNA and is stimulated by replication protein A to unwind the damaged DNA substrate in a strand-specific manner |
| Q39672854 | FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. |
| Q40239174 | FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth |
| Q39308862 | FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer |
| Q41543745 | Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. |
| Q36602573 | Fanconi anaemia genes and susceptibility to cancer |
| Q37865169 | Fanconi anaemia: from a monogenic disease to sporadic cancer |
| Q24306790 | Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair |
| Q92947905 | Fanconi anemia and the underlying causes of genomic instability |
| Q36888171 | Fanconi anemia and ubiquitination |
| Q30449304 | Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction |
| Q39915440 | Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture |
| Q35913754 | Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility |
| Q34597176 | Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. |
| Q26852818 | Fanconi anemia pathway defects in inherited and sporadic cancers |
| Q34623241 | Fanconi anemia protein FANCD2 inhibits TRF1 polyADP-ribosylation through tankyrase1-dependent manner |
| Q37069628 | Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy |
| Q42021055 | Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer |
| Q80342295 | Fanconi anemia: Fanconi anemia, breast and embryonal cancer risk revisited |
| Q40098123 | Fanconi anemia: genetic analysis of a human disease using chicken system. |
| Q37512640 | Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia |
| Q37431184 | Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif |
| Q38252487 | Genetic counseling for Fanconi anemia: crosslinking disciplines. |
| Q34282323 | Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. |
| Q36754598 | Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer |
| Q81412971 | Genetic subtyping of Fanconi anemia by comprehensive mutation screening |
| Q34686817 | Genomic instability in mice is greater in Fanconi anemia caused by deficiency of Fancd2 than Fancg |
| Q41878162 | Genomic stability: FANCJ-dependent G4 DNA repair |
| Q47870583 | Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma |
| Q48428199 | Guido Fanconi (1892-1979): a jack of all trades. |
| Q37033851 | Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome |
| Q42906135 | Hereditary head and neck tumors |
| Q37977556 | Hereditary ovarian cancer: beyond the usual suspects |
| Q39308806 | Histone chaperone activity of Fanconi anemia proteins, FANCD2 and FANCI, is required for DNA crosslink repair |
| Q24634556 | How the fanconi anemia pathway guards the genome |
| Q24324635 | Human Nbp35 is essential for both cytosolic iron-sulfur protein assembly and iron homeostasis |
| Q35752656 | Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype |
| Q84489787 | Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T |
| Q24685928 | Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair |
| Q64387799 | Immunodeficiency, radiosensitivity, and the XCIND syndrome |
| Q53250307 | Impaired immune function in children with Fanconi anaemia. |
| Q39949263 | Impaired synthesis of heme oxygenase-1 in Fanconi anemia cells can be rescued by transfection of Fanconi wild-type cDNA. |
| Q28285540 | Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans |
| Q51286905 | Impairment of fetal hematopoietic stem cell function in the absence of Fancd2. |
| Q43944556 | Increased apoptosis is linked to severe acute GVHD in patients with Fanconi anemia |
| Q36088380 | Inferring the regulatory network behind a gene expression experiment. |
| Q35582803 | Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells |
| Q50193922 | Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness |
| Q37175571 | Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes |
| Q27643858 | Insights into Fanconi Anaemia from the structure of human FANCE |
| Q24337192 | Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome |
| Q36876769 | Investigation of FANCA gene in Fanconi anaemia patients in Iran |
| Q40961568 | Involvement of FANCD2 in Energy Metabolism via ATP5α. |
| Q36349060 | In Vivo RNAi Screen Unveils PPARγ as a Regulator of Hematopoietic Stem Cell Homeostasis |
| Q39883780 | Knockdown of alphaII spectrin in normal human cells by siRNA leads to chromosomal instability and decreased DNA interstrand cross-link repair. |
| Q33974355 | Knockdown of mu-calpain in Fanconi anemia, FA-A, cells by siRNA restores alphaII spectrin levels and corrects chromosomal instability and defective DNA interstrand cross-link repair |
| Q39508334 | Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients |
| Q35585979 | Macrophages prevent human red blood cell reconstitution in immunodeficient mice |
| Q26746868 | Mechanisms of interstrand DNA crosslink repair and human disorders |
| Q57490090 | Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells |
| Q36485336 | Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts |
| Q24621696 | Molecular pathogenesis and clinical management of Fanconi anemia |
| Q49646612 | Multifaceted Fanconi Anemia Signaling. |
| Q37356517 | Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del |
| Q36299696 | Mutated Fanconi anemia pathway in non-Fanconi anemia cancers |
| Q47857337 | Mutations in Fanconi anemia genes and the risk of esophageal cancer |
| Q36717910 | Myelodysplastic syndromes: the complexity of stem-cell diseases |
| Q34657712 | Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair |
| Q39350013 | New insights into redox response modulation in Fanconi's anemia cells by hydrogen peroxide and glutathione depletors |
| Q64386995 | No formation of DNA double-strand breaks and no activation of recombination repair with UVA |
| Q36878452 | Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage |
| Q37208542 | Nuclear alpha spectrin: Critical roles in DNA interstrand cross-link repair and genomic stability |
| Q38841737 | Nuclear α Spectrin Differentially Affects Monoubiquitinated Versus Non-Ubiquitinated FANCD2 Function After DNA Interstrand Cross-Link Damage |
| Q38981040 | Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression |
| Q37001945 | Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells |
| Q39982793 | Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation |
| Q38013077 | Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management |
| Q30499016 | Oxidative stress resistance in Deinococcus radiodurans |
| Q24615080 | PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene |
| Q33851843 | Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality |
| Q34340923 | Posttranslational modification of mammalian AP endonuclease (APE1). |
| Q34082330 | Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector |
| Q37218373 | RAD51D- and FANCG-dependent base substitution mutagenesis at the ATP1A1 locus in mammalian cells |
| Q38834205 | RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells |
| Q38971720 | Rapid Lentiviral Transduction Preserves the Engraftment Potential of Fanca-/- Hematopoietic Stem Cells |
| Q52663131 | Redox-sensitive signaling in inflammatory T cells and in autoimmune disease. |
| Q39875666 | Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis |
| Q36220736 | Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein |
| Q37993652 | Replication fork dynamics and the DNA damage response. |
| Q38128316 | Role of E3 ubiquitin ligases in lung cancer |
| Q35030835 | Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks |
| Q37578363 | Squamous cell carcinoma of base of tongue in a patient with Fanconi's anemia treated with radiation therapy: case report and review of literature |
| Q39622929 | Stem cell characteristics of cell sub-populations in cell lines derived from head and neck cancers of Fanconi anemia patients |
| Q40260881 | Stem cell collection and gene transfer in Fanconi anemia |
| Q34572286 | Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex |
| Q90003769 | Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia |
| Q27023204 | Targeting DNA damage response in cancer therapy |
| Q37452985 | Targeting an Achilles' heel of cancer with a WRN helicase inhibitor |
| Q38817102 | Targeting the ATR-CHK1 Axis in Cancer Therapy |
| Q37098481 | Targeting the ubiquitin-proteasome system for cancer therapy |
| Q36591289 | Telomere maintenance and human bone marrow failure |
| Q40183559 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents |
| Q38285213 | The Fanconi anemia ID2 complex: dueling saxes at the crossroads |
| Q35024542 | The Fanconi anemia pathway and ICL repair: implications for cancer therapy |
| Q28756516 | The Fanconi anemia pathway and ubiquitin |
| Q34000660 | The Fanconi anemia protein, FANCG, binds to the ERCC1-XPF endonuclease via its tetratricopeptide repeats and the central domain of ERCC1. |
| Q36543285 | The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair |
| Q37526483 | The MRE11 complex: starting from the ends. |
| Q40063188 | The Role of PALB2 in the DNA Damage Response and Cancer Predisposition. |
| Q37696424 | The SNM1/Pso2 family of ICL repair nucleases: from yeast to man. |
| Q37446105 | The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation |
| Q37808102 | The role of BRCA mutation testing in determining breast cancer therapy |
| Q37045395 | The role of DNA damage repair in aging of adult stem cells |
| Q38217924 | The role of ubiquitin-binding domains in human pathophysiology |
| Q35232277 | The ups and downs of DNA repair biomarkers for PARP inhibitor therapies |
| Q56625730 | Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles |
| Q34813119 | Tumor hypoxia and genetic alterations in sporadic cancers |
| Q24336838 | UBE2W interacts with FANCL and regulates the monoubiquitination of Fanconi anemia protein FANCD2 |
| Q34422921 | Understanding disease mechanisms with models of signaling pathway activities. |
| Q37577923 | Update on genetic predisposition to breast cancer |
| Q37144651 | Welcome the family of FANCJ-like helicases to the block of genome stability maintenance proteins |
| Q37154365 | Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway |
| Q51796409 | XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. |
Search more.